Loading...
Derniers manuscrits de la plateforme
-
Olivia Le Saux, Maude Ardin, Justine Berthet, Sarah Barrin, Morgane Bourhis, et al.. Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma. Nature Communications, 2024, 15 (1), pp.5932. ⟨10.1038/s41467-024-47000-5⟩. ⟨hal-04655437⟩
-
Stéphane Dalle, Estelle Verronese, Axelle N’kodia, Christine Bardin, Céline Rodriguez, et al.. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients. OncoImmunology, 2024, 13 (1), pp.2372118. ⟨10.1080/2162402X.2024.2372118⟩. ⟨hal-04632685⟩
-
Anthony Di Roio, Margaux Hubert, Laurie Besson, Marion Bossennec, Céline Rodriguez, et al.. MDR1-expressing CD4+T cells with Th1.17 features resist to neoadjuvant chemotherapy and are associated with breast cancer clinical response. Journal for Immunotherapy of Cancer, 2023, 11 (11), ⟨10.1136/jitc-2023-007733⟩. ⟨hal-04379561⟩
-
Lise Mangiante, Nicolas Alcala, Alexandra Sexton-Oates, Alex Di Genova, Abel Gonzalez-Perez, et al.. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nature Genetics, 2023, 55 (4), pp.607-618. ⟨10.1038/s41588-023-01321-1⟩. ⟨inserm-04062865⟩
-
Benoîte Mery, Christine Ménétrier-Caux, Laure Montané, Pierre-Etienne Heudel, Isabelle Ray-Coquard, et al.. Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. Breast Cancer, 2023, 15, pp.311 - 325. ⟨10.2147/bctt.s400055⟩. ⟨hal-04210158⟩
Chiffres clés
11
Publications avec texte intégral